Red Light Holland enters the market of legal magic truffles

Exploring the recreational and potential medical use of psychedelics

Most people have heard of ‘magic mushrooms’, but they may be unfamiliar with their fungi cousin magic truffles. Magic truffles are legal and very popular in the Netherlands and are well known for their hallucinegic properties that result in psychedelic effects. What is less well known is that truffles have a number of potential health benefits related to reducing anxiety and depression, lifting mood, and freeing the mind. The price for 10 grams of truffles (the maximum recommended dose for a beginner) is between 10 to 15 Euro in Amsterdam.

Red Light Holland Corp. (CSE: TRIP | FSE:4YX) (“RLH”) is in the ‘magic truffle’ business. The Company aims to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands. Their business revolves around a premium brand of magic truffles. Sales are conducted through existing Dutch Smartshops storefront operators and an advanced e-commerce platform. The Netherlands is a country with a long-standing, established, legal magic truffles market.

Red Light Holland is now starting to commercialize their premium magic truffles in the Netherlands for both recreational and eventual medicinal use

Source: Company presentation

In some surprising news in August, RLH announced that it had commenced its “magic truffles growth operation in the Netherlands, months ahead of schedule…” Red Light Holland has “expedited the build out of its approximately 3,000 square feet, custom built, indoor growing, production and distribution facility of the Company, in Horst, the Netherlands (the “Facility“) and has commenced growing its first crop of magic truffles.”

RLH has also ordered 10,000 units of Psychedelic Truffles Microdosing Packs from McSmart (one of the Netherlands’ prominent truffle growers, distributors and Smart Shop owners), to launch the Microdosing Packs within the Netherlands as early as September 2020. RLH plans to sell these via three Smart Shops operated by McSmart, as well as through Red Light Holland’s proposed e-commerce platform and McSmart’s existing e-commerce platform.

Red Light Holland has also been on a hiring spree adding 7 new high-level members to their team with a wide variety of both business and medical (psychedelics) knowledge and experience. One of the new hires, Sarah Hashkes from RadixMotion, will focus on developing an innovative virtual reality shopping experience (VR Module, due by Q4 2020) for Dutch Smart Shops and e-commerce platforms. Sarah Hashkes is the CEO of RadixMotion and a scientific researcher with knowledge on microdosing and is RLH’s new Scientific Advisor. Part of her mandate is to educate the public about psilocybin, the active ingredient in magic truffles.

The project also includes having a “VR Avatar”, expected to be online by Q3 2020. The VR Avatar is expected to assist Red Light Holland’s larger efforts towards reducing the stigma associated with magic truffles and other psychedelic substances. The Avatar, RLH explains, is to help the novice: “Now imagine shopping for something new – but wanting to truly experience it before purchasing? Pretty cool idea, right? What we are aiming to create here is a virtual reality experience that potential consumers can use before buying our Microdose Packs. This way, they can experience what the effects of microdosing magic truffles would be like, to help with their personal comfort and understanding before actually purchasing our product.”

Sounds rather cool to me. I think it will be quite popular for the curious to try this out. What do readers think?

Red Light Holland is currently growing three different strains of magic truffles and expects to have an initial batch of approximately 100,000 grams of magic truffles available in late October, 2020.

Red Light Holland carves out a unique market niche

Source: Company presentation

Closing remarks

Red Light Holland is moving surprisingly fast to commercialize and promote their product range of premium magic truffles. Considering the Company only listed in Canada this year in late May, then in Germany in June, it is quite amazing that operations have already begun and they are already producing their own magic truffles.

Red Light Holland trades on a market cap of just C$19m as investors are yet to learn about the Company, and their large potential to rapidly expand and create revenues in the lucrative magic truffles market in the Netherlands. Exciting times are ahead for Red Light Holland with a new innovative VR Avatar virtual reality shopping experience, with sales and revenues all not that far away in Q3 and Q4 of this year.




Cannabis Today and Tomorrow the #1 Cash Crop for 2019

There is little doubt that cannabis has had a great past few years especially with the legalisation of recreational use in Canada on October 17, 2018. What’s next for 2019?

Canadian companies will look to expand as the US may legalise further states in 2019

With other legal cannabis spending projected to reach $100 billion in the US by 2029, industry insiders see big things ahead for the American cannabis movement. This could also see Canadian companies look to the US to expand their ever growing portfolios. Currently there are ten US states that have now legalized cannabis, and 33 that allow medical use. The following US states are considered a reasonable chance to legalise cannabis in 2019 – Connecticut, Illinois, Minnesota, New Hampshire, New Jersey, New Mexico, New York, Rhode Island, and Vermont.

Other countries that may legalise cannabis soon

The following are some countries that look likely to follow the Canadian lead in making recreational use of cannabis legal: Colombia, Jamaica, Spain, Portugal, Australia, and perhaps the United States.

Canada cannabis sales should boom but more retail outlets will be needed

Recreational use of cannabis has been legal in Canada since Oct. 17, 2018; however so far Ontario consumers have only been able to buy the product online. A lottery system will be used to select who will be issued a retail license as only 25 of the first wave will be issued by April 1, 2019. So far in Alberta the province has approved 65 cannabis stores throughout the province, though it initially said there could be 250 by late 2019. Demand for quality marijuana since legalization remains strong however there is reported to be a shortage of retail outlets.

Some Cannabis companies will look to expand into hemp products

The recent passing of the farm bill by the US congress legalizes hemp, an industry estimated to be worth $867 billion. This will lead to a very strong 2019 for hemp products especially in the US.

A brief view of some of the cannabis participants listed in Canada

FinCanna Capital Corp. (CSE: CALI | OTCQB: FNNZF) is one of two publicly traded pure-play Cannabis royalty companies uniquely focused on investing in licensed medical cannabis businesses with a focus on California. The Company’s vision is to be the capital partner of choice for high growth, best-in-class businesses, focused on the licensed U.S. medical cannabis industry.

Global Cannabis Applications Corp. (CSE: APP | OTCQB: FUAPF) is a global leader in designing, developing, marketing and acquiring innovative data technologies for the cannabis industry. They are doing this by applying artificial intelligence, blockchain, and cryptocurrency to improve cannabis health sciences, under their Citizen Green platform.

NanoSphere Health Sciences Inc. (CSE: NSHS) is a nano biotechnology company paving the way in the development of innovative delivery systems for cannabinoids and medications. The Company provides the only patented “nano-particle delivery system” to transport therapeutic agents directly into the bloodstream for maximum absorbency.

SOL Global Investments Corp. (CSE: SOL | OTCQB: SOLCF) is an international cannabis company with a focus on legal U.S. states. With recent hemp law changes in the US, the Company is energized by the opportunities and looks forward to developing a hemp strategy in this still-evolving industry. They have partnered with the University of Miami in a R&D program that compliments its strategic investments and partnerships across cultivation, distribution, and retail complement.

WeedMD Inc. (TSXV: WMD | OTCQX: WDDMF) is a Canadian producer and distributor of medicinal cannabis. The Company also collects vital data that also contributes to ongoing research. By doing so, they are able to provide healthcare providers and their patients with the information they need to fully comprehend the role medical cannabis can play in their pain-management regimen.

Cannabis can clearly become one of the world’s largest cash crops. With so many byproducts and potential in a growing market investors will need to be to be patient for governments to sort out procedures and legal licensing.

2019 looks to be the year when we may start to see greater opportunities in the US as attitudes change towards the plant and more states are possibly legalised. Just remember the legal cannabis industry is in its infancy and will need time to grow, both in Canada and abroad.




WeedMD’s Kraft on how distribution agreements are critical to the cannabis business

“At WeedMD we are very proud of the foundation we have built from the production platform. We have got 1,200 kilograms coming out of our original indoor facility in Aylmer, Ontario. With our expansion of a hybrid greenhouse in Strathroy we have 20,000 kilograms coming onboard of quality quads coming out of flower and then an additional 30,000 kilograms of production for oil. We have to find a home for that product. Clearly these distribution agreements are critical to the business and hitting our revenue and sales milestones.” States Michael Kraft, Chairman of WeedMD Inc. (TSXV: WMD), in an interview with InvestorIntel Corp. CEO Tracy Weslosky.

Tracy Weslosky: Michael you introduced me to the cannabis industry sector when it first started. What was that 2013/2014? 

Michael Kraft: Beginning of 2014.

Tracy Weslosky: Michael I see that you just put out your third quarter results. I read you have increased revenue by 461% year-over-year prior to opening of Canada’s adult use market. Can you just talk to us about a couple of your highlights from your third quarter results because there was quite a few results/updates? 

Michael Kraft: Sure. I think the most significant is our topline of sales increased from approximately $350,000 to an excess of $2 million dollars. Behind that is our growth in patients, medical patients, which is paramount to our business. In addition we continued to generate revenue from the sale of genetics domestically to other LPs, which is part of our MO to seed the industry. Notably is also our first export shipment to Australia. It is actually the first legal shipment of genetics into Australia that we are very proud about. We also see growth coming from the export of our genetic business.

Tracy Weslosky: Call me an old fashioned investor, but we like things like distribution for instance. I noticed you have a deal with Shoppers Drug Mart and several distribution channels including an announcement with Lifford Cannabis Solutions. Can you tell us more about your distribution infrastructure?

Michael Kraft: At this juncture distribution is critical. We meet as a company the focus whether be it for the board or management level as distribution, distribution and distribution. WeedMD has successfully secured relationships with a number of provincial agencies ranging from BC, Alberta through to Ontario through to Nova Scotia. We have also secured a notable distribution agreement supply agreement with Shoppers Drug Mart. In summary WeedMD has secured critical distribution platforms across Canada. That includes the retail channel with Shoppers Drug Mart for the drugstore chain.  

Tracy Weslosky: My take on this is the reason why you are securing all of these critical distribution channels is because of your production. What I see, a half a million square feet of cultivation. Correct me. Tell me about your actual production Michael.

Michael Kraft: At WeedMD we are very proud of the foundation we have built from the production platform. We have got 1,200 kilograms coming out of our original indoor facility in Alymer, Ontario. With our expansion of a hybrid greenhouse in Strathroy we have 20,000 kilograms coming onboard of quality quads coming out of flower and then an additional 30,000 kilograms of production for oil. We have to find a home for that product. Clearly these distribution agreements are critical to the business and hitting our revenue and sales milestones…to access the complete interview, click here

Disclaimer: WeedMD Inc. is an advertorial member of InvestorIntel Corp.




Rewards abound with an app that provides a Loyalty Love-In for the investment market.

My computer screen saver has a “Join Microsoft Rewards” program that promises me value. Win points, secure rewards, it’s a win-win. But this loyalty love-in game is a hard one to win, unless of course, you have the team, the technology, and are proving that you can build an online community with trust?

Who does this in today’s day and age when many of us have quit visiting sites that require username and passwords, understanding the algorithms of data collection and associated artificial intelligence may or may not be our friend? Global Cannabis Applications Corp.’s (“GCAC”) (CSE: APP | OTCQB: FUAPF) Brad Moore has identified this formula by doing what no other reward program does through the Citizen Green Community, and will pay us like no other for our data.

The investor I had breakfast with this morning said to me: “You know Tracy, everyone is an investor nowadays — they want to buy stock on Friday and sell it on Monday.”

Not a licensed investment advisor, so this is not a buy recommendation, but having been in the public markets since 2001, I, like many in our audience, am a self-directed investor and want to see my money grow. So count me in, as 1 of the 650,000 members and climbing of Citizen Green.

Over the years we have seen many companies whose share price seems undervalued. And to make this column more interesting, I decided to go on record with my interest in GCAC and buy CAD$2500 worth of Global Cannabis Applications’ CSE: APP. The plan? Hold it for 12-weeks, and let you know what I sell it for. Let me be clearer. Today, I bought 15,000 shares of $APP.C at CAD$0.165 for a total of $2475 which I will sell on February 14, 2019.

So why Global Cannabis Applications Corp. or GCAC as many refer to it?

For me, I always have my interest engaged by the leadership and in this case, it was the CEO Brad Moore’s engaging and data building plan-of-action when he said in his last ii-interview with me: “We are basically building the smartest budtender in the world”.

“I like their Citizen Green platform because of the information.” Starts our Social Media Director Sharron Clayton. Then she goes on to add: “The database is very informative. Basically, it takes all the guess work out of how to select what medical cannabis is right for each patient.”

Is this why they use the trading symbol “APP”? I asked our production manager Sam Markham who has a real handle on the cannabis market on our team and to whom we regularly consult with. Not impressed with my witticism, he explained that GCAC’s Citizengreen.io platform creates a loyalty program that covers the industry and is not tied to a single location, giving customers the ability to still be part of the “community” without being tied to a single store, expanding GCAC’s reach.

If you think about it, when have we ever received loyalty points for buying prescriptions? Better yet, Sam in our team tells me we get points for providing follow-up reviews of the prescription. With incentive for community interaction through the reward of Citizen Green Coins or CGC’s, GCAC is collecting valuable information for the medical market and data towards helping in the management of every cannabis “pain to strain” issue and enhancing our life experience.

But consider? If the Citizengreen.io platform can do it right for the cannabis market, as Matt Bohlsen wrote a week ago become the “world’s first end-to-end – from patient to regulator – medical cannabis data solution” is there any reason this might not step over the cannabis medical wall and right into the lap of the global medical market? Now in this future hypothetical scenario, the $APP.C shareholder would be the “citizen in the green”…

On a final note, we reviewed some highlights on CSE: APP this morning that we thought we might share with you —

  1. History. Past price activity has shown acceptance by market to higher market cap (REF: Traded in 01/18 @.99 per share or 5x current mkt value)
  2. Trading. Trades on both CDN and US stock Exchanges (CSE: APP | OTCQB: FUAPF) for investor access
  3. Sponsorship. Good broker sponsorship (Trapeze Capital Corp EST 1999)
  4. Market Cap. Current Low market cap offers price opportunity with manageable share float. (Current Mkt Cap about $11.5 million/57.5 million shares outstanding.)
  5. Volume. Trades enough daily share volumes for long- and short-term investors. (Average daily volume 300k shares)

We also liked the overview on the Citizen Green Platform written by InvestorIntel’s Matt Bohlsen in a story titled The world’s first end to end, from seed to sale, patient to regulator, medical cannabis data solution is here

The Citizen Green platform is the world’s first end to end, from seed to sale, patient to regulator, medical cannabis data solution. It uses 6 core technologies: mobile applications, artificial intelligence, smart databases, blockchain and digital reward tokens; all designed to speed the process of quality shared data. The objective is to use advanced technology to create an online community portal. Every cannabis strain affects patients in a different way, and this is about sharing personal knowledge across a social media style platform to inform other members of personal experiences. By joining the Citizen Green community a medicinal user can now find more information on their particular condition through other users experiences and learn how best to treat it. Transactions and earnings will be in the form of “Citizen Green Token”, GCAC’s cryptocurrency. Citizen Green Tokens, which fuel the Citizen Green economy, are earned for contributing information, and experiences and can be used to receive discounts on purchases and access a full range of related services. There is even a Citizen Green phone app, which as of Q2 2018 already had 650,000 users. GCAC plans to more than double the number of users by Q2 2019 to reach 1.4m global users.

If you missed last week’s interview, GCAC to Sponsor MJBizCon 2018 in Las Vegasclick here




On track to have more than 500,000 square feet of cultivation for the medical cannabis sector

The benefits of medical cannabis are becoming increasingly evident and recognized as an acceptable form of treatment. The global medical cannabis market size in 2017 was ~US$ 11 billion. The market value is expected to reach ~US$ 37 billion by 2023, for a CAGR of ~22% during 2017-2023. The US market will follow a similar trajectory.

The US medical and recreation marijuana market forecast to grow strongly

The US medical and recreation marijuana market forecast to grow strongly

WeedMD Inc. (TSXV: WMD | OTCQX: WDDMF) is a Canadian producer and distributor of medicinal cannabis. The Company collects vital data that also contributes to ongoing research. By doing so, they are able to provide healthcare providers and their patients with the information they need to fully comprehend the role medical cannabis can play in their pain-management regimen, and enable them to make informed decisions regarding their overall health.

WeedMD operates two facilities: a 26,000 sq. ft. indoor facility in Aylmer, Ontario and a state-of-the-art greenhouse facility located in Strathroy, Ontario. The greenhouse currently has 44,000 square feet of licensed space in production and is expected to have a total footprint of more than 500,000 square feet.

The last few weeks have been good for WeedMD

On November 13, 2018 it was announced that WeedMD has secured a licence from Health Canada to sell cannabis cultivated at its greenhouse facility in Strathroy, Ontario. The original licence, issued under the Access to Cannabis for Medical Purposes Regulations, was successfully migrated to a licence under the Cannabis Act and its regulations.

Keith Merker, CEO of WeedMD said: “We are thrilled to secure approval to begin selling the medical-grade cannabis that we’ve been cultivating at our production facility in Strathroy. The Company continues to meet its production milestones on schedule and on budget. Beyond that, we are on track to have more than 500,000 square feet of cultivation online by 2019.”

On October 31, 2018 WeedMD announced it had signed a multiyear retail sales distribution agreement with Lifford Cannabis Solutions to represent WeedMD’s premium cannabis brands and products for the adult-use retail market in British Columbia and Alberta.

Brett Moon, SVP, Sales and Marketing at WeedMD, said: “With the onset of legalization, WeedMD’s products are garnering the attention of a discerning and knowledgeable cannabis audience.”

Back in August 2018 the first harvest was announced from the Strathroy facility. The first harvest was completed in early September and resulted in an impressive yield from the first 10,000 square foot grow room. The Company marked the event with a WeedMD “First Harvest” celebration party, a community open house that welcomed well over 120 guests that included WeedMD’s Board of Directors, local government, business leaders, investors, media representatives and employees.

WeedMD’s Harvest party in Aylmer

There has been a lot of activity at WeedMD in the last few months including:

  • Piloting a proprietary genome tracking program along with Blockstrain to protect cannabis genetics and intellectual property and launching Blockstrains revolutionary “genome to sale” software. (October 24)
  • Partnering with a leading Quebec product formulation laboratory to spearhead cannabis product development. (October 23)
  • Developing a pilot project to convert a popular Toronto-based medical cannabis center to a WeedMD cannabis education center. (October 16)
  • Completing its first shipment of adult use cannabis. (September 28)
  • Exporting cannabis genetics to Australia’s Medifarm. (September 13)

WeedMD is having great success in such a huge growing market, and with so much activity going on one would assume that they must be looking forward to the next “harvest celebration party”.

Canada’s new legislation will see so many new markets opening up supporting the cannabis industry and WeedMD’s development.




The world’s first end to end, from seed to sale, patient to regulator, medical cannabis data solution is here.

Secondary industries can quite often do surprisingly well as often there is less competition. Global Cannabis Applications Corp. (CSE: APP | OTCQB: FUAPF) (“GCAC”) is a global leader in designing, developing, marketing and acquiring innovative data technologies for the cannabis industry. They are doing this by applying artificial intelligence, blockchain, and cryptocurrency to improve cannabis health sciences, under their Citizen Green platform.

Citizen Green

The Citizen Green platform is the world’s first end to end, from seed to sale, patient to regulator, medical cannabis data solution. It uses 6 core technologies: mobile applications, artificial intelligence, smart databases, blockchain and digital reward tokens; all designed to speed the process of quality shared data. The objective is to use advanced technology to create an online community portal. Every cannabis strain affects patients in a different way, and this is about sharing personal knowledge across a social media style platform to inform other members of personal experiences. By joining the Citizen Green community a medicinal user can now find more information on their particular condition through other users experiences and learn how best to treat it. Transactions and earnings will be in the form of “Citizen Green Token”, GCAC’s cryptocurrency. Citizen Green Tokens, which fuel the Citizen Green economy, are earned for contributing information, and experiences and can be used to receive discounts on purchases and access a full range of related services. There is even a Citizen Green phone app, which as of Q2 2018 already had 650,000 users. GCAC plans to more than double the number of users by Q2 2019 to reach 1.4m global users.

New Citizen Green Website launched

October 2018 was a busy month for GCAC. They announced a major marketing and sales campaign starting October 31, 2018, targeting medical cannabis dispensaries across North America, through their Citizengreen.io website. The new website will have all the information necessary for medical cannabis retailers to learn about the smart technology driven Citizen Green Community. The website is part of an aggressive marketing and sales campaign to introduce the Citizen Green Community to all medical cannabis retailers starting with over 3,300 retail dispensaries with the majority located in California, Colorado, and Arizona.

Brad Moore, CEO of GCAC, stated: “We are launching the Citizengreen website to support our marketing and sales efforts of the Citizen Green Community to thousands of medical cannabis retailers in the United States.”

Previously in October the Company announced it had signed a letter of intent with Cannact LLC, a seasoned distributor of cannabis technology and products in California. The license agreement will integrate the Citizen Green patient-care solution onto Cannact’s platform with potential integration for related cannabis retailer partners. The Cannact team has established relationships with over fifty retail partners and dispensaries.

CEO Brad Moore added: “Cannact is the first of many licensed producers and dispensaries who will seek Citizen Green’s innovated solutions to improve health, safety and patient outcomes in the cannabis industry.”

GCAC has also launched its innovative Citizen Green patient-care solution to the global cannabis marketplace, starting with California which is experiencing explosive growth.

The chart above shows the Company’s achievements to date and targets ahead, including reaching $1M per month in revenue by Q4 2018. GCAC are tapping into the multi-billion-dollar global cannabis industry, where a lack of trusted cannabis related information is yet to exist. Multiple jurisdictions around the world have legalized or are moving toward legalization of medical use including Australia, Canada, Chile, Colombia, Czech Republic, Israel, Mexico and 30 other U.S. states. Having partnerships with leading sources of consumer and medical data could see Global Cannabis Applications Corp. becoming a pioneer in the medical cannabis data storage area. Keep an eye on this social media style business (CannaBook?) (Fannabis?), as their marketing strategies are on track for bigger things to come.




WeedMD CEO on Hiku and the cannabis market today.

“It does not impact WeedMD really in any way shape or form. Hiku brought an interesting aspect to our potential business combination in that they brought retail. WeedMD has always been in existence as an LP with a strong production platform and a strong medical platform and a really thriving business. When Hiku goes away WeedMD is left just as such, a strong platform with cultivation, medical research, partnerships, a great staff that is doing wonderful things every day.” states Keith Merker, CEO of WeedMD Inc. (TSXV: WMD), in an interview with InvestorIntel Corp. CEO Tracy Weslosky.

Tracy Weslosky: Keith there is a lot about WeedMD on the news with the Hiku deal. You have got $50 million in the bank. You got a Shoppers Drug deal. Talk to me about how this is going to impact you. 

Keith Merker: It does not impact WeedMD really in any way shape or form. Hiku brought an interesting aspect to our potential business combination in that they brought retail. WeedMD has always been in existence as an LP with a strong production platform and a strong medical platform and a really thriving business. When Hiku goes away WeedMD is left just as such, a strong platform with cultivation, medical research, partnerships, a great staff that is doing wonderful things every day.

Tracy Weslosky: Speaking of retail and deals, I see you just signed a supply agreement with the British Columbia Liquor Distribution Branch. For those of us that may not understand this, can you tell us a little bit more about it? 

Keith Merker: The wonderful thing that WeedMD has on the go is that we have a massive cultivation expansion underway in Strathroy, Ontario quite near our original facility in Aylmer, Ontario. This facility with the current retrofit that is underway will have over 20 tons of production online, annual run rate capacity by end of 2018. Where is all that wonderful product going to find a home? To your point we have announced recently a deal with the BC Liquor Distribution Branch. We have announced a deal with the Alberta agency who will be distributing product in that province. To your earlier point, we have also announced a deal with Shoppers Drug Mart. We have got more in the hopper, more good news coming. If you can do the math on the numbers I can tell you that all of these various jurisdictions and partners that are looking for product are very pleased and happy and demanding more than we can perhaps even offer currently and for the foreseeable future. Our product is going to find a home and we are going to put out some good numbers as a result.

Tracy Weslosky: Keith we have been watching WeedMD for some time and the InvestorIntel audience is starting to move into the cannabis market. They are a little apprehensive. Can you tell us what the competitive advantages are for WeedMD? I mean, obviously you have got a great deal of cash. I think perhaps your target may be of interest to our audience. 

Keith Merker: Sure. Going back to the very early days when the company was formed and founded, some of the members of the original founding team and some of the folks that still continue with us to this day come from very extensive backgrounds in long-term care and seniors care. As a result we have a, let us call it a secret sauce when it comes to that particular demographic. We have utilized that to sign up a number of different long-term care residences under supply and preferred educational provider agreements…to access the complete interview, click here

Disclaimer: WeedMD Inc. is an advertorial member of InvestorIntel Corp.